ahlam1399
09-29-2016, 10:40 AM
Actelion to investigate all-oral MS combination therapy
ZURICH (Reuters) - Swiss biotech group Actelion Ltd will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), it said, calling it the first study of this approach for treating the neurological disorder.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=8LRq-GxGMGU:7xRWhuWHKF8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8LRq-GxGMGU:7xRWhuWHKF8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=8LRq-GxGMGU:7xRWhuWHKF8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8LRq-GxGMGU:7xRWhuWHKF8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=8LRq-GxGMGU:7xRWhuWHKF8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/8LRq-GxGMGU
ZURICH (Reuters) - Swiss biotech group Actelion Ltd will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), it said, calling it the first study of this approach for treating the neurological disorder.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=8LRq-GxGMGU:7xRWhuWHKF8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8LRq-GxGMGU:7xRWhuWHKF8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=8LRq-GxGMGU:7xRWhuWHKF8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=8LRq-GxGMGU:7xRWhuWHKF8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=8LRq-GxGMGU:7xRWhuWHKF8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/8LRq-GxGMGU